Figure 4. Chromatin bridge formation in HT1080 cells after treatment by Pt-tpy and its three derivatives, Pt-cpym, Pt-vpym and Pt-ttpy at telophase/cytokinesis.

(A) Cells after drug treatment were stained with antibodies against LAP2. LAP2 allows visualization and quantification of fine chromatin bridges that are too thin to be spotted with DAPI staining. (B) The percentage of cells presenting chromatin bridges in telophase/cytokinesis upon treatment with Pt-cpym, Pt-vpym, Pt-ttpy, and Pt-tpy quantified using LAP2 as a marker. ^*Indicates P-value < 0.05; ^** P < 0.01.